Safrazine
Clinical data | |
---|---|
Other names | 4-benzo[1,3]dioxol-5-ylbutan-2-ylhydrazine; [3-(3,4-(methylenedioxy)phenyl)-1-butyl]hydrazine; 2-piperonylisopropylhydrazine |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C11H16N2O2 |
Molar mass | 208.261 g·mol−1 |
3D model (JSmol) | |
SMILES
|
Safrazine (Safra) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was introduced as an antidepressant in the 1960s, but has since been discontinued.[1]
See also
References
- ↑ Morton I, Morton IK, Hall JM (31 October 1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 251–. ISBN 978-0-7514-0499-9.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.